Neuraxis

Neuraxis Liabilities

The The Liabilities of Neuraxis (NRXS) as of Nov 22, 2026 is 3.00 M USD. In the previous year, The Liabilities was 2.69 M USD — a change of 11.70% (higher).

Liabilities

3.00 MUSD

YoY

11.70%

Last updated:

In 2025, Neuraxis's total liabilities amounted to 3.00 M USD, a 11.70% difference from the 2.69 M USD total liabilities in the previous year.

The Neuraxis Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2020
1.15 M USD
Jan 1, 2021
1.59 M USD
Jan 1, 2022
7.05 M USD
Jan 1, 2023
1.91 M USD
Jan 1, 2024
2.69 M USD
Jan 1, 2025
3.00 M USD
The Neuraxis Liabilities history
YEARLiabilitiesYoY
3.00 MUSD+11.70%
2.69 MUSD+40.63%
1.91 MUSD-72.89%
7.05 MUSD+344.74%
1.59 MUSD+38.43%
1.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuraxis Stock analysis

What does Neuraxis do? NeurAxis, Inc. generates revenue through the development and commercialization of neuromodulation therapies targeting chronic conditions in pediatric patients. The company's primary product, the B-Stim device, is designed for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children aged 11-18. The FDA pipeline includes additional indications such as chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome, which expand the potential market reach of their PENFS technology. The company's focus on pediatric applications differentiates its offerings within the neuromodulation sector. The Percutaneous Electrical Nerve Field Stimulation (PENFS) technology underpins both the B-Stim and IB-Stim systems, which are specifically tailored for pediatric use. These devices are intended for patients 11-18 years of age with functional abdominal pain linked to IBS, positioning NeurAxis to address unmet medical needs in adolescent healthcare. The FDA's involvement in the pipeline process ensures regulatory alignment for expanding indications, which supports market adoption and potential revenue streams. NeurAxis targets healthcare providers and pediatric specialists who treat chronic conditions in adolescents. The company's products are positioned to address functional gastrointestinal disorders and related symptoms, offering an alternative to traditional pharmacological treatments. By focusing on specific age groups and medical indications, NeurAxis aims to capture a niche segment within the broader neuromodulation market. Neuraxis is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Neuraxis's Liabilities

Neuraxis's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Neuraxis's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Neuraxis's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Neuraxis's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Neuraxis’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Neuraxis stock

The Liabilities of Neuraxis is 3.00 M USD in 2025.

The Liabilities of Neuraxis changed from 2.69 M USD to 3.00 M USD, representing a 11.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Neuraxis since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Neuraxis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuraxis

All Key Metrics — Neuraxis